We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Sponsor content
34 result(s) found, displaying 11 to 20
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for ONBEVZI bevacizumab 400 mg/16mL concentrated injection for intravenous infusion vial.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for ONBEVZI bevacizumab 100 mg/4mL concentrated injection for intravenous infusion vial.
-
Australian public assessment report (AusPar)Onbevzi (bevacizumab) is a biosimilar of Avastin. Onbevzi has been approved to treat a range of cancers either as a monotherapy or in combination with other anti-cancer medicines
-
Prescription medicine decision summaryOnbevzi (bevacizumab) is a biosimilar of Avastin. Onbevzi has been approved to treat a range of cancers either as a monotherapy or in combination with other anti-cancer medicines.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for HADLIMA adalimumab 40 mg/0.4 mL solution for injection in pre-filled syringe.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for HADLIMA adalimumab 40 mg/0.4 mL solution for injection in PushTouch auto-injector.
-
Prescription medicine registrationActive ingredients: Bevacizumab.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for Samsung Bioepis AU Pty Ltd - Surgical procedure kit, ophthalmic, medicated, single-use.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for BYOOVIZ ranibizumab 10 mg/mL solution for injection vial.
-
Australian public assessment report (AusPar)Byooviz (ranibizumab) for the treatment of neovascular age-related macular degeneration etc.